Vault-13

ENTERA BIO LTD ENTX

SHS · Common Stock · CUSIP M40527109

4 institutional holders +0 vs Q4 2019
1,990,2442.0m shares reported held*
10.9% of all shares outstanding*
$3.8mreported value*
1 new 0 added 0 reduced 1 sold out net bought ≈ $137.1k (+68.7k shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 18.2m as of 2019-12-31, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $1.90.

Trends to Q1 2020

Institutional holders

Managers reporting a position, each quarter

024Q4 19: 4Q1 20: 44Q4 19Q1 20
Numbers
QuarterHolders
Q4 20194
Q1 20204

Biggest buyers

Phoenix Financial Ltd. New +69,355+69.4k

Biggest sellers

UBS Group AG Sold out -620-620

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
BIOTECHNOLOGY VALUE FUND L P 13D · may seek influence new · filed 2026-08-04
Stated purposeThe Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, … Full filing
10.0% new 17.2m≈ $30.5m 2026-08-04
OPKO HEALTH, INC. 13G · passive investor new · filed 2025-04-02 8.1% new 3.7m≈ $6.5m 2025-04-02
TCG Crossover GP III, LLC 13G · passive investor new · filed 2026-08-04 7.1% new 12.3m≈ $21.7m 2026-08-04
Vivo Opportunity Fund Holdings, L.P. 13G · passive investor new · filed 2026-08-04 6.9% new 11.8m≈ $20.9m 2026-08-04

Fell to 5% or below in the last year: Longitude Capital Partners V, LLC (4.6%, 2026-08-04), Seven Fleet Capital Management LP (4.1%, 2026-08-04)

Insider purchases and sales in Q1 2020

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

None reported in Q1 2020.

Holders, Q1 2020

#ManagerLocationShares Value% of their portfolioChangeShares change
1 Knoll Capital Management, LLC 3.08% of their portfolio MIAMI, FL 1,741,3631.7m $3.3m $3.3m 3.08% Unchanged
2 Wildcat Capital Management, LLC 0.18% of their portfolio NEW YORK, NY 179,526179.5k $369.0k $369.0k 0.18% Unchanged
3 Phoenix Financial Ltd. 0.01% of their portfolio Givatayim, L3 69,35569.4k $138.0k $138.0k 0.01% New
4 CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio BIRMINGHAM, AL 00 $0 $0 0.00% Unchanged